Identification of New Potential Prognostic and Predictive Markers in High-Grade Osteosarcoma Using Whole Exome Sequencing.
genetics
osteosarcoma
prognosis
treatment
whole exome sequencing
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Jun 2023
13 Jun 2023
Historique:
received:
22
05
2023
revised:
08
06
2023
accepted:
11
06
2023
medline:
29
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Conventional high-grade osteosarcoma (OS) is the most common primary cancer of bone and it typically affects the extremities of adolescents. OS has a complex karyotype, and molecular mechanisms related to carcinogenesis, progression and resistance to therapy are still largely unknown. For this reason, the current standard of care is associated with considerable adverse effects. In this study, our aim was to identify gene alterations in OS patients using whole exome sequencing (WES) to find new potential prognostic biomarkers and therapeutic targets. We performed WES on formalin-fixed paraffin-embedded (FFPE) biopsy materials collected from 19 patients affected by conventional high-grade OS. The clinical and genetic data were analyzed according to response to therapy, presence of metastasis and disease status. By comparing good and poor responders to neoadjuvant therapy, we detected a clear prevalence of mutations in the
Identifiants
pubmed: 37373240
pii: ijms241210086
doi: 10.3390/ijms241210086
pmc: PMC10298506
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Annu Rev Biochem. 2018 Jun 20;87:263-294
pubmed: 29709199
Sarcoma. 2012;2012:627254
pubmed: 22685381
Nat Commun. 2015 Dec 03;6:8940
pubmed: 26632267
Sci Rep. 2015 Sep 18;5:14283
pubmed: 26381817
Lab Invest. 2022 Apr;102(4):391-400
pubmed: 34921235
Oncoimmunology. 2019 Jun 16;8(9):e1629258
pubmed: 31428527
Int Orthop. 2011 Dec;35(12):1847-53
pubmed: 21359502
Clin Genet. 2015 Feb;87(2):148-54
pubmed: 24476420
Cancers (Basel). 2020 Jul 31;12(8):
pubmed: 32751922
Children (Basel). 2022 May 22;9(5):
pubmed: 35626936
Curr Oncol Rep. 2016 May;18(5):29
pubmed: 26984416
J Thorac Oncol. 2018 Aug;13(8):1217-1221
pubmed: 29654927
Orphanet J Rare Dis. 2007 Jan 23;2:6
pubmed: 17244349
Virchows Arch. 2020 Jan;476(1):147-157
pubmed: 31741049
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Nat Commun. 2021 Dec 3;12(1):7064
pubmed: 34862364
Elife. 2020 Jan 15;9:
pubmed: 31939734
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Cell Cycle. 2012 Oct 15;11(20):3837-50
pubmed: 22983061
Jt Dis Relat Surg. 2023;34(1):196-206
pubmed: 36700283
Int J Surg Oncol. 2021 Apr 26;2021:8843325
pubmed: 33996154
Cancer. 1985 Oct 1;56(7):1515-21
pubmed: 3861228
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9
pubmed: 19066271
Cancer. 1982 Mar 15;49(6):1221-30
pubmed: 6174200
Bioinformatics. 2019 May 1;35(9):1579-1581
pubmed: 30304370
Eur J Cancer. 2005 Sep;41(14):2079-85
pubmed: 16115755
Int J Biostat. 2007;3(1):Article 11
pubmed: 22550651
Bone. 2017 Sep;102:69-79
pubmed: 27760307
J Biol Chem. 2016 Apr 29;291(18):9690-9
pubmed: 26953344
Hered Cancer Clin Pract. 2009 Feb 17;7(1):4
pubmed: 19338683
Bone Joint J. 2020 Jun;102-B(6):795-803
pubmed: 32475245
Hum Genomics. 2014 Dec 11;8:20
pubmed: 25496518
Adv Anat Pathol. 2018 Jul;25(4):217-222
pubmed: 29668499
Front Oncol. 2021 Apr 07;10:595527
pubmed: 33898301